NVO vs VRTX: stock comparison and AI forecast
Novo Nordisk A S (NVO) and Vertex Pharmaceuticals Inc / Ma (VRTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NVO Novo Nordisk A S
- Price
- $40.30 -12.0% · 6M
- Market Cap
- $179.09B
- P/E Ratio
- 3.0x
- Size
- large-cap
- AI Forecast
VRTX Vertex Pharmaceuticals Inc / Ma
- Price
- $542.50 +26.9% · 6M
- Market Cap
- $137.50B
- P/E Ratio
- 34.9x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- NVO is 1.3 times larger than VRTX by market capitalization ($179.09B against $137.50B).
- NVO trades at 3.0 times trailing earnings, VRTX at 34.9 times.
- Over the last six months VRTX returned +26.9% and NVO -12.0%.
- NVO turns 34.0% of its revenue into net income, against 30.7% for VRTX.
- NVO carries 1.80 times debt per unit of equity, against 0.57 times for VRTX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NVO | VRTX |
|---|---|---|
| Market Cap | $179.09B | $137.50B |
| P/E Ratio | 2.99x | 34.93x |
| P/B Ratio | – | 6.58x |
| EPS | $13.48 | $15.53 |
| Book Value/Share | – | $82.49 |
| Revenue/Share | $34.48 | $51.10 |
| FCF/Share | $9.66 | $12.63 |
Profitability & Margins
| Metric | NVO | VRTX |
|---|---|---|
| ROE | 176.6% | 19.0% |
| ROA | 63.1% | 12.2% |
| ROIC | 132.4% | 15.5% |
| Gross Margin | 83.4% | 85.5% |
| Operating Margin | 43.0% | 33.2% |
| Net Margin | 34.0% | 30.7% |
| EBT Margin | 42.8% | 36.8% |
| Tax Rate | 20.6% | 16.5% |
Financial Health
| Metric | NVO | VRTX |
|---|---|---|
| Current Ratio | 0.80x | 2.34x |
| Quick Ratio | 0.57x | 1.89x |
| D/E Ratio | 1.80x | 0.57x |
| Financial Leverage | 2.80x | 1.57x |
| Interest Coverage | – | 245.8x |
| Working Capital | -$6.79B | $6.69B |
Cash Flow
| Metric | NVO | VRTX |
|---|---|---|
| Operating Cash Flow | $64.99B | $3.69B |
| Free Cash Flow | $42.93B | $3.20B |
| Capital Spending | -$22.06B | -$492M |
| OCF Growth YoY | 115.7% | -0.6% |
| FCF Growth YoY | 0.0% | -4.0% |
| FCF/Sales | 28.0% | 24.7% |
| CapEx/Sales | 14.4% | 3.8% |
Operational Efficiency
| Metric | NVO | VRTX |
|---|---|---|
| Asset Turnover | 1.86x | 0.40x |
| Receivables Turnover | – | 5.6x |
| Inventory Turnover | 3.4x | 0.8x |
| Fixed Assets Turnover | – | 7.6x |
| Days Sales Outstanding | – | 65 days |
| Days Inventory | 108 days | 437 days |
| Payables Period | – | 92 days |
| Cash Conversion Cycle | – | 410 days |
Income Statement
| Metric | NVO | VRTX |
|---|---|---|
| Total Revenue | $153.22B | $12.95B |
| Operating Income | $65.83B | $4.30B |
| Net Income | $52.04B | $3.98B |
| R&D Expense | $23.79B | $4.25B |
| SG&A Expense | – | $2.41B |
| Cost of Goods Sold | $25.45B | $1.87B |
Dividend & Shareholder Information
| Metric | NVO | VRTX |
|---|---|---|
| Shares Outstanding | 4444M | 253M |
| Net Income Growth | 104.6% | 8.2% |
| EPS Growth | 24.9% | 8.6% |
NVO vs VRTX: stock comparison and AI forecast
Which is bigger, NVO or VRTX?
NVO is 1.3 times larger than VRTX by market capitalization ($179.09B against $137.50B).
Which is cheaper on earnings, NVO or VRTX?
NVO trades at 3.0 times trailing earnings, VRTX at 34.9 times.
Which stock performed better over the last six months, NVO or VRTX?
Over the last six months VRTX returned +26.9% and NVO -12.0%.
Which one does Intratio's AI model rank higher, NVO or VRTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.